NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price & News $8.35 -0.04 (-0.48%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$8.30▼$8.4950-Day Range$7.37▼$8.7752-Week Range$7.20▼$15.43Volume2.47 million shsAverage Volume2.94 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability BioCryst Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside79.6% Upside$15.00 Price TargetShort InterestBearish17.10% of Shares Sold ShortDividend StrengthN/ASustainability-1.85Upright™ Environmental ScoreNews Sentiment0.35Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector620th out of 983 stocksBiological Products, Except Diagnostic Industry100th out of 164 stocks 3.3 Analyst's Opinion Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, BioCryst Pharmaceuticals has a forecasted upside of 79.6% from its current price of $8.35.Amount of Analyst CoverageBioCryst Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.10% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 3.53%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.Environmental SustainabilityThe Environmental Impact score for BioCryst Pharmaceuticals is -1.85. Previous Next 2.4 News and Social Media Coverage News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioCryst Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest16 people have searched for BCRX on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.MarketBeat Follows3 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions79.05% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($1.03) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About BioCryst Pharmaceuticals (NASDAQ:BCRX) StockBioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.Read More Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Stock News HeadlinesMay 31, 2023 | finance.yahoo.comBioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology CongressMay 31, 2023 | seekingalpha.comBioCryst Pharmaceuticals: An Updated ViewJune 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 22, 2023 | markets.businessinsider.comBioCryst Pharma Receives Approval Of ORLADEYO From Public Health Institute Of ChileMay 22, 2023 | finance.yahoo.comBioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of ChileMay 14, 2023 | americanbankingnews.comBrokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $15.00May 14, 2023 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded by StockNews.com to HoldMay 12, 2023 | americanbankingnews.comReviewing BioCryst Pharmaceuticals (NASDAQ:BCRX) and ImmunityBio (NASDAQ:IBRX)June 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 9, 2023 | finance.yahoo.comBioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) institutional shareholders had a great week as one-year returns increased after a 13% gain last weekMay 9, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Issued By HC WainwrightMay 8, 2023 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to "Buy" at StockNews.comMay 3, 2023 | msn.comBioCryst gains 14% most since February after Q1 2023 resultsMay 3, 2023 | finance.yahoo.comBioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call TranscriptMay 3, 2023 | msn.comBioCryst Clocks 37.8% Revenue Growth In Q1 On Solid New Patient GrowthMay 3, 2023 | seekingalpha.comBioCryst Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 3, 2023 | msn.comBioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66MMay 3, 2023 | finance.yahoo.comBioCryst Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 27, 2023 | finance.yahoo.comBioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)April 26, 2023 | americanbankingnews.comBioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on WednesdayApril 24, 2023 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from Needham & Company LLCApril 23, 2023 | americanbankingnews.comEvercore ISI Trims BioCryst Pharmaceuticals (NASDAQ:BCRX) Target Price to $10.00April 21, 2023 | bizjournals.comPharma with Bham presence takes $300M loan to pay down debtApril 20, 2023 | msn.comEvercore ISI Group Maintains Biocryst Pharmaceuticals (BCRX) Outperform RecommendationApril 20, 2023 | msn.comNeedham Reiterates Biocryst Pharmaceuticals (BCRX) Buy RecommendationApril 20, 2023 | bizjournals.comDurham pharma takes $300M loan to pay down debtApril 19, 2023 | finance.yahoo.comBioCryst to Report First Quarter 2023 Financial Results on May 3See More Headlines BCRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCRX Company Calendar Last Earnings5/03/2023Today6/02/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BCRX CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees358Year Founded1986Price Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+80.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-247,120,000.00 Net Margins-78.10% Pretax Margin-77.03% Return on EquityN/A Return on Assets-42.51% Debt Debt-to-Equity RatioN/A Current Ratio5.76 Quick Ratio5.44 Sales & Book Value Annual Sales$270.83 million Price / Sales5.81 Cash FlowN/A Price / Cash FlowN/A Book Value($1.74) per share Price / Book-4.79Miscellaneous Outstanding Shares188,930,000Free Float179,488,000Market Cap$1.57 billion OptionableOptionable Beta1.98 Social Links Key ExecutivesJon P. StonehousePresident, Chief Executive Officer & DirectorMichael L. JonesExecutive Director-FinanceAnthony DoyleChief Financial OfficerHelen M. ThackrayChief Research & Development OfficerRyan ArnoldChief Medical OfficerKey CompetitorsNovavaxNASDAQ:NVAXAgenusNASDAQ:AGENHalozyme TherapeuticsNASDAQ:HALOVericelNASDAQ:VCELKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInsiders & InstitutionsGolden State Equity PartnersBought 10,925 shares on 6/1/2023Ownership: 0.006%ProShare Advisors LLCSold 4,388 shares on 5/26/2023Ownership: 0.018%Ameriprise Financial Inc.Sold 497,936 shares on 5/22/2023Ownership: 0.177%Putnam Investments LLCSold 1,654 shares on 5/22/2023Ownership: 0.021%Arete Wealth Advisors LLCBought 23,973 shares on 5/22/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions BCRX Stock - Frequently Asked Questions Should I buy or sell BioCryst Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares. View BCRX analyst ratings or view top-rated stocks. What is BioCryst Pharmaceuticals' stock price forecast for 2023? 7 equities research analysts have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their BCRX share price forecasts range from $10.00 to $30.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 80.1% from the stock's current price. View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts. How have BCRX shares performed in 2023? BioCryst Pharmaceuticals' stock was trading at $11.48 at the start of the year. Since then, BCRX shares have decreased by 27.4% and is now trading at $8.33. View the best growth stocks for 2023 here. When is BioCryst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our BCRX earnings forecast. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its earnings results on Wednesday, May, 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. The biotechnology company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $71.44 million. The firm's quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) EPS. What ETFs hold BioCryst Pharmaceuticals' stock? ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and First Trust Small Cap Growth AlphaDEX Fund (FYC). What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO? 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). What is BioCryst Pharmaceuticals' stock symbol? BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX." Who are BioCryst Pharmaceuticals' major shareholders? BioCryst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.85%), State Street Corp (6.03%), Avoro Capital Advisors LLC (5.52%), Pictet Asset Management SA (2.97%), Assenagon Asset Management S.A. (2.64%) and Fisher Asset Management LLC (2.26%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioCryst Pharmaceuticals' stock price today? One share of BCRX stock can currently be purchased for approximately $8.33. How much money does BioCryst Pharmaceuticals make? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $1.57 billion and generates $270.83 million in revenue each year. The biotechnology company earns $-247,120,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. How many employees does BioCryst Pharmaceuticals have? The company employs 358 workers across the globe. How can I contact BioCryst Pharmaceuticals? BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314. This page (NASDAQ:BCRX) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.